Sherry Yang, M.D., Ph.D.
Dr. Sherry Yang joined the Cancer Diagnosis Program as Medical Officer and Program Director in 2019. She oversees a research portfolio in the Program and has been involved in special program projects, such as biomarker review in Precision Medicine trials. Dr. Yang reviews and advises on procedures for the evaluation of prognostic and predictive markers for targeted therapies, immunotherapy, and chemotherapy. She serves as a biomarker reviewer for Cancer Therapy Evaluation Program (CTEP)-sponsored clinical trials. She is a member of the NCI ComboMATCH Molecular Biomarker and Specimen Management Committee. Dr. Yang initiated and implemented the treatment-associated and outcome-type weighted prognostic biomarker project at the Program. Progress has been made through large breast cancer cohort and phase III TAILORx trial studies.
Through her role as the Chief of National Clinical Target Validation Laboratory from 2006 to 2019, her laboratory developed and validated pharmacodynamic, response or toxicity biomarkers, as well as prognostic and predictive biomarkers to targeted therapy and conventional therapy.
Dr. Yang joined the National Cancer Institute in 2001 after her service at the Johns Hopkins Oncology Center, Baltimore, Maryland. Her 100 plus publications have over 7000 citations and she is a recipient of several biomarker-related awards and innovations. Focused on biomarker-driven cancer treatment, Dr. Yang has been an editor of Handbook of Therapeutic Biomarkers in Cancer since 2013.
Selected Publications
- Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt Pathways in Cancer Stem Cells: Clinical Update and Future Directions. Nature Review Clinical Oncology, 2015 Apr 7. doi: 10.1038/nrclinonc.2015.61.
- Nguyen D, Yu J, Reinhold WC; Yang SX. Association of independent prognostic factors and treatment modality with survival and recurrence outcomes in breast cancer. JAMA Netw Open. 2020;3(7):e207213.
- Yang SX and Dancey J (eds), Handbook of Therapeutic Biomarkers in Cancer, Taylor & Francis group, 2nd Edition, ISBN 978-981-4877-00-8.
- Yang SX, Hollingshead M, Rubinstein L, Nguyen D, Larenjeira AA, Kinders R, Difilippantonio D and Doroshow JH. TET2 and DNMT3A mutations and exceptional response to 4’-thio-2'-deoxycytidine in human solid tumor models. J of Hematology and Oncology, 26;14(1):83, 2021.
- Yang SX, Yu J, Wang M. 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial. J Natl Compr Canc Netw. 2024 Jul 17;22(6):376-381.